Compound for treating cancer and diabetes

Patent metadata

Field	Value
Publication number	US-9808434-B2
Application number	US-201615173628-A
Country	US
Kind code	B2
Filing date	Jun 4, 2016
Priority date	Jan 27, 2011
Publication date	Nov 7, 2017
Grant date	Nov 7, 2017

Abstract

One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.

First claim

The invention claimed is:

1. A method of treating a cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of 1,3-bis (3,5-dichlorophenyl) urea (COH-SR4), a salt thereof, or stereoisomers thereof, wherein the cancer is selected from the group consisting of melanoma, and lung cancer.

2. The method of claim 1 , wherein the cancer is melanoma.

3. The method of claim 2 , wherein the melanoma is metastatic melanoma.

4. The method of claim 1 , wherein the cancer is lung cancer.

5. The method of claim 4 , wherein the lung cancer is non-small cell lung cancer.

6. The method of claim 1 , wherein the lung cancer is metastatic lung cancer.

7. The method of claim 2 , wherein the pharmaceutical composition further comprising one or more second anticancer agents selected from the group consisting of TMZ, SN38, CPT-11, and 5-FU.

8. The method of claim 1 , further comprising administering chemotherapy to the subject.

9. The method of claim 2 , further comprising administering chemotherapy to the subject.

10. The method of claim 4 , further comprising administering chemotherapy to the subject.

11. The method of claim 1 , wherein the pharmaceutical composition is administered by topical administration, mucosal administration, oral administration, nasal administration, vaginal administration, rectal administration, parenteral administration, transdermal administration, intravenous injection, subcutaneous administration, intramuscular injection, inhalation, or ophthalmic administration.

12. The method of claim 2 , wherein the pharmaceutical composition is administered by topical administration, mucosal administration, oral administration, nasal administration, vaginal administration, rectal administration, parenteral administration, transdermal administration, intravenous injection, subcutaneous administration, intramuscular injection, inhalation, or ophthalmic administration.

13. The method of claim 4 , wherein the pharmaceutical composition is administered by topical administration, mucosal administration, oral administration, nasal administration, vaginal administration, rectal administration, parenteral administration, transdermal administration, intravenous injection, subcutaneous administration, intramuscular injection, inhalation, or ophthalmic administration.

14. The method of claim 1 , wherein the pharmaceutical composition is administered at a daily dose of about 0.005 to about 25 mg/kg, about 0.01 to about 10 mg/kg, or about 0.05 to about 1 mg/kg, body weight of COH-SR4, a salt thereof, or stereoisomers thereof.

15. The method of claim 2 , wherein the pharmaceutical composition is administered at a daily dose of about 0.005 to about 25 mg/kg, about 0.01 to about 10 mg/kg, or about 0.05 to about 1 mg/kg, body weight of COH-SR4, a salt thereof, or stereoisomers thereof.

16. The method of claim 4 , wherein the pharmaceutical composition is administered at a daily dose of about 0.005 to about 25 mg/kg, about 0.01 to about 10 mg/kg, or about 0.05 to about 1 mg/kg, body weight of COH-SR4, a salt thereof, or stereoisomers thereof.

Assignees

• Hope City

Inventors

• Rahbar Samuel
• Figarola James L
• Lincoln Christopher
• Horne David
• Mooney Rachael
• Polewski Monika
• Somlo George
• Yang Lixin
• Awasthi Sanjay
• Singhal Sharad
• Singhal Jyotasana

Classifications

• A61K31/17 Primary

  having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64) · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K31/495

  having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) · CPC title

• C07D229/00

  Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms · CPC title